No Data
No Data
Jefferies Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $25
Bausch + Lomb Stock Extends Gains as Jefferies Describes It as an 'Undervalued Asset'
Express News | B of A Securities Reinstates Underperform on Bausch & Lomb, Announces $18 Price Target
BofA Securities Downgrades Bausch + Lomb Corp.(BLCO.US) to Sell Rating, Announces Target Price $18
Bausch & Lomb Edges Higher After Confirming Sales Process
Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
Benjamin’s : New CEO